Scarica l'app Stockscreener
12.24
1.09%
-0.135
Dopo l'orario di chiusura:
12.25
0.005
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FGEN Giù?
Forum
Previsione
Precedente Chiudi:
$12.38
Aprire:
$12.33
Volume 24 ore:
30,480
Relative Volume:
0.62
Capitalizzazione di mercato:
$49.52M
Reddito:
$147.75M
Utile/perdita netta:
$-284.23M
Rapporto P/E:
-4.1792
EPS:
-2.93
Flusso di cassa netto:
$-317.54M
1 W Prestazione:
+7.60%
1M Prestazione:
+15.19%
6M Prestazione:
+42.97%
1 anno Prestazione:
+31.31%
Intervallo 1D:
$12.06
$12.58
Intervallo di 1 settimana:
$11.02
$12.58
Portata 52W:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Nome
Fibrogen Inc
Settore
Industria
Telefono
415-978-1200
Indirizzo
350 BAY STREET, SAN FRANCISCO, CA
Confronta FGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
12.24 | 50.06M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Downgrade | Stifel | Buy → Hold |
| 2023-06-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Aggiornamento | Stifel | Hold → Buy |
| 2023-01-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-09-22 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-07-16 | Downgrade | Stifel | Buy → Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Downgrade | Mizuho | Buy → Neutral |
| 2021-03-31 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-03-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-26 | Iniziato | Raymond James | Underperform |
| 2020-07-10 | Ripresa | Stifel | Buy |
| 2020-05-01 | Iniziato | Cowen | Market Perform |
| 2020-04-27 | Iniziato | BofA/Merrill | Neutral |
| 2019-05-29 | Ripresa | Goldman | Neutral |
| 2019-05-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Iniziato | Piper Jaffray | Neutral |
| 2019-02-11 | Ripresa | Stifel | Buy |
| 2018-12-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2017-08-08 | Reiterato | Leerink Partners | Outperform |
| 2017-08-08 | Reiterato | Stifel | Buy |
| 2017-07-21 | Downgrade | Goldman | Buy → Neutral |
| 2017-07-11 | Iniziato | Jefferies | Buy |
| 2016-02-11 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
| 2015-12-04 | Iniziato | Citigroup | Buy |
| 2015-09-23 | Iniziato | Lake Street | Hold |
| 2015-07-29 | Iniziato | Citigroup | Buy |
| 2015-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2014-12-09 | Iniziato | Stifel | Buy |
Mostra tutto
Fibrogen Inc Borsa (FGEN) Ultime notizie
William Blair Remains a Hold on FibroGen (FGEN) - The Globe and Mail
FibroGen stock advances as H.C. Wainwright reiterates Buy rating on FG-3246 progress - Investing.com
FGEN: HC Wainwright & Co. Reiterates 'Buy' Rating with $43 Targe - GuruFocus
FibroGen (FGEN) Launches Phase 2 Trial for Antibody-Drug Conjuga - GuruFocus
FibroGen initiates phase 2 trial of FG-3246 for prostate cancer - Investing.com Australia
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - The Manila Times
FibroGen Initiates Phase 2 Trial for FG-3246 in Metastatic Castration-Resistant Prostate Cancer, Evaluating Companion PET Imaging Agent FG-3180 - Quiver Quantitative
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a - GlobeNewswire
First-in-Class CD46 Targeting ADC: FibroGen's FG-3246 Enters Phase 2 Trial for Advanced Prostate Cancer - Stock Titan
Treasury Yields: Is FibroGen Inc stock a buy or sell2025 Trade Ideas & Reliable Momentum Entry Alerts - خودرو بانک
Market Catalysts: Is FibroGen Inc vulnerable to short sellersVolume Spike & Free Safe Entry Trade Signal Reports - خودرو بانک
Fed Watch: Why is FibroGen Inc stock going upJuly 2025 Price Swings & Low Drawdown Trading Strategies - khodrobank.com
Aug Volume: Will FibroGen Inc stock benefit from M A2025 Historical Comparison & Capital Protection Trade Alerts - خودرو بانک
What is FibroGen Incs revenue forecast2025 Trading Volume Trends & Weekly Watchlist of Top Performers - khodrobank.com
Volatility Watch: Can FibroGen Inc sustain its profitabilityWall Street Watch & Smart Allocation Stock Tips - khodrobank.com
Meme Stocks: Is FibroGen Inc stock a value trapBull Run & Breakout Confirmation Alerts - خودرو بانک
Wall Street Zen Upgrades FibroGen (NASDAQ:FGEN) to "Hold" - MarketBeat
Growth Value: Will FibroGen Inc benefit from rising consumer demandQuarterly Trade Review & Consistent Income Trade Recommendations - خودرو بانک
FibroGen appoints David DeLucia CFO - MSN
Aug Selloffs: Is FibroGen Inc. affected by consumer sentimentGap Up & Real-Time Volume Triggers - khodrobank.com
FibroGen Sells Subsidiary to AstraZeneca for $220M - msn.com
FOMO Trade: What is OXLCGs valuation compared to sectorDay Trade & Daily Entry Point Trade Alerts - خودرو بانک
China State Administration for Market Regulation approves sale of FibroGen China to AstraZeneca - MSN
SEC Charges Public Company and Executive with Disclosure Fraud - The National Law Review
Breakout Move: Is Spectral AI Inc Equity Warrant stock heavily shortedJuly 2025 Catalysts & Expert-Curated Trade Recommendations - khodrobank.com
Fibrogen leads drug developer stock gains on China sale, FDA update - BioWorld MedTech
S P Trends: Can FibroGen Inc sustain its profitabilityWeekly Risk Summary & AI Powered Buy/Sell Recommendations - خودرو بانک
Downgrade Watch: What is the target price for FibroGen Inc stockWeekly Trade Recap & Proven Capital Preservation Methods - خودرو بانک
Hedge Fund Moves: Can FibroGen Inc be the next market leaderJuly 2025 Chart Watch & Fast Momentum Entry Tips - خودرو بانک
Will FibroGen Inc benefit from government policyQuarterly Market Review & Technical Entry and Exit Alerts - خودرو بانک
Buyback Watch: What is the long term forecast for FibroGen Inc stockRecession Risk & Weekly High Return Stock Forecasts - خودرو بانک
How to build a custom watchlist for FibroGen Inc.Earnings Summary Report & AI Driven Stock Movement Reports - newser.com
Inflation Data: Is FibroGen Inc stock a value trap2025 Momentum Check & Safe Entry Point Identification - خودرو بانک
Understanding FibroGen Inc.’s price movementMarket Activity Summary & Capital Efficiency Focused Strategies - newser.com
Support Test: Can Polyrizon Ltd. outperform under higher oil pricesQuarterly Risk Review & Free Real-Time Volume Trigger Notifications - خودرو بانک
Best data tools to analyze FibroGen Inc. stockPrice Action & Safe Investment Capital Preservation Plans - newser.com
Predicting FibroGen Inc. trend using moving averagesEarnings Summary Report & Capital Efficient Trading Techniques - newser.com
Live market analysis of FibroGen Inc.Earnings Growth Summary & Stock Portfolio Risk Control - newser.com
Developing predictive dashboards with FibroGen Inc. dataJuly 2025 Update & Low Drawdown Trading Techniques - newser.com
How to forecast FibroGen Inc. trends using time seriesPortfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com
Will FibroGen Inc. price bounce be sustainable2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - newser.com
Detecting support and resistance levels for FibroGen Inc.Gap Up & Weekly Return Optimization Plans - newser.com
FRAUD AND MANIPULATION—N.D. Cal.: Former FibroGen CMO charged after allegedly reverse engineering drug results - VitalLaw.com
FibroGen (NASDAQ:FGEN) Upgraded at Wall Street Zen - Defense World
$1.25 million penalty for FibroGen over ‘false and misleading statements’ case - The Pharma Letter
FibroGen at H.C. Wainwright: Strategic Moves and Future Prospects By Investing.com - Investing.com Nigeria
FibroGen at H.C. Wainwright: Strategic Moves and Future Prospects - Investing.com
Is FibroGen Inc. stock a buy or sell2025 Biggest Moves & Growth-Oriented Investment Plans - Lancaster City Council
FibroGen To Pay SEC $1.25M Over Drug Mistatements - Law360
Can FibroGen Inc. reach all time highs this yearJuly 2025 Review & Smart Money Movement Tracker - beatles.ru
Fibrogen Inc Azioni (FGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):